Leuprolide
- Generic Name
- Leuprolide
- Brand Names
- Camcevi, Eligard, Fensolvi, Lupaneta Pack 1-month, Lupron, Lupron Depot-ped, Viadur, Zeulide Depot
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N16O12
- CAS Number
- 53714-56-0
- Unique Ingredient Identifier
- EFY6W0M8TG
- Background
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the...
- Indication
Leuprolide is indicated for the treatment of advanced prostate cancer and as palliative treatment of advanced prostate cancer.
It is also used for the treatment of pediatric patients with central precocious puberty (CPP).
...
- Associated Conditions
- Advanced Prostate Cancer, Anemia, Central Precocious Puberty (CPP), Endometriosis
- Associated Therapies
- Palliative Treatment
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
- Conditions
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 264
- Registration Number
- NCT05440383
- Locations
- 🇯🇵
Clinical Resarch Site, Multiple Locations, Japan
RElugolix VErsus LeUprolide Cardiac Trial
- Conditions
- Biochemically Recurrent Prostate CarcinomaLocalized Prostate CarcinomaStage I Prostate Cancer AJCC V8Stage II Prostate Cancer AJCC V8Stage IIA Prostate Cancer AJCC V8Stage IIB Prostate Cancer AJCC V8Stage IIC Prostate Cancer AJCC V8Stage III Prostate Cancer AJCC V8Stage IIIA Prostate Cancer AJCC V8Stage IIIB Prostate Cancer AJCC V8
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Emory University
- Target Recruit Count
- 93
- Registration Number
- NCT05320406
- Locations
- 🇺🇸
Emory Proton Therapy Center, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2024-04-23
- Target Recruit Count
- 94
- Registration Number
- NCT05206682
- Locations
- 🇨🇳
Shanghai Jiaotong University xinhua hospital, Shanghai, Shanghai, China
Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer（MAPS）
- Conditions
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Target Recruit Count
- 182
- Registration Number
- NCT05087706
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, Shanghai, China
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2050
- Registration Number
- NCT05050084
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 14417
- Registration Number
- NCT04897958
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2478
- Registration Number
- NCT04513717
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Scottsdale, Scottsdale, Arizona, United States
Role of Suppression of Endometriosis With Progestins Before IVF-ET
- Conditions
- Interventions
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- National Research Centre, Egypt
- Target Recruit Count
- 134
- Registration Number
- NCT04500743
- Locations
- 🇪🇬
Minia Infertility research unit, Minya, Egypt
Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer
- Conditions
- Interventions
- Locations
- 🇺🇸
Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 280
- Registration Number
- NCT04302454
- Locations
- 🇳🇱
Radiotherapiegroep, Deventer, Overijssel, Netherlands
🇳🇱Isala, Zwolle, Overijssel, Netherlands
🇳🇱Radiotherapy Institute Friesland, Leeuwarden, Friesland, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.